Table of Contents
Hepatitis B and C are major causes of chronic liver disease worldwide, often leading to cirrhosis and hepatocellular carcinoma. Managing hepatitis in patients with existing liver cirrhosis presents unique challenges and requires careful consideration of antiviral therapy options.
Understanding Liver Cirrhosis and Hepatitis
Liver cirrhosis is a progressive scarring of the liver tissue resulting from long-term liver damage. It impairs liver function and increases the risk of liver failure. When combined with hepatitis infection, the disease progression accelerates, making treatment more complex.
Goals of Antiviral Therapy in Cirrhotic Patients
The primary objectives of antiviral therapy in patients with cirrhosis are:
- Suppress viral replication
- Reduce liver inflammation and fibrosis
- Prevent progression to decompensation
- Lower the risk of hepatocellular carcinoma
Antiviral Treatment Options
Several antiviral agents are available for hepatitis B and C. Choice of therapy depends on the type of hepatitis, liver function status, and potential drug interactions.
Hepatitis B Virus (HBV) Treatment
For HBV, nucleos(t)ide analogues such as entecavir and tenofovir are preferred due to their potency and low resistance rates. In cirrhotic patients, these drugs help prevent disease progression and reduce the risk of hepatocellular carcinoma.
Hepatitis C Virus (HCV) Treatment
Direct-acting antivirals (DAAs) have revolutionized HCV treatment, offering high cure rates. In patients with cirrhosis, treatment regimens may need adjustment based on liver function and prior treatment history.
Special Considerations in Cirrhotic Patients
Patients with liver cirrhosis require close monitoring during antiviral therapy. Potential complications include:
- Decompensation episodes
- Drug-induced hepatotoxicity
- Development of hepatocellular carcinoma
Regular assessment of liver function, viral load, and screening for liver cancer are essential components of management.
Conclusion
Antiviral therapy plays a critical role in managing hepatitis in patients with co-existing liver cirrhosis. Tailoring treatment plans to individual patient needs and close monitoring can improve outcomes and reduce disease progression.